Dtsch Med Wochenschr 2012; 137(48): 2495-2497
DOI: 10.1055/s-0032-1327304
Kommentar | Commentary
Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Renale Denervation bei Hypertonie – wann, für wen und für wen nicht?

Renal denervation in hypertension: When? For whom? And for whom not?
L. C. Rump
1   Klinik für Nephrologie, Heinrich-Heine-Universität Düsseldorf
› Institutsangaben
Weitere Informationen

Publikationsverlauf

04. Oktober 2012

08. November 2012

Publikationsdatum:
20. November 2012 (online)

 
  • Literatur

  • 1 Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-1478
  • 2 Bernard C. Lecons sur les proprietes et les alterations pathologiques des liquides de l´organisme. Paris: Bailliere et Fils; 1859
  • 3 DiBona GF, Esler M. Translational Medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245-53
  • 4 DiBona GF. Neural control of the kidney: past, present and future. Hypertension 2003; 41: 621-624
  • 5 Grassi G, Seravalle G, Brambilla G et al. Novel antihypertensive therapy: renal sympathetic nerve ablation and carotid baroreceptor stimulation. Curr Hypertens Rep 2012; Sep 26. [Epub ahead of print]
  • 6 Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250-1257
  • 7 Hoppe UC, Brandt MC, Wachter R. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6: 270-6
  • 8 Krum H, Schlaich MP, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension. Lancet 2009; 373: 1275-1281
  • 9 Lopez AD, Mathers CD, Ezzati M et al. Global and regional burden of disease and risk factors 2001. Lancet 2006; 367: 1747-1757
  • 10 Löwel H, Meisinger C, Heier M et al. Epidemiologie der arteriellen Hypertonie in Deutschland. Ausgewählte Ergebnisse bevölkerungsrepräsentativer Querschnittstudien. Dtsch Med Wochenschr 2006; 131: 2586-2491
  • 11 Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946
  • 12 Mahfoud F, Vonend O, Bruck H et al. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie. Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch Med Wochenschr 2011; 136: 2418-24
  • 13 Persu A, Renkin J, Thijs L et al. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60: 596-606
  • 14 Redberg RF. Informed strategies for treating coronary disease: comment on "initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease". Arch Intern Med 2012; 27,172: 321
  • 15 Rump LC, Amann K, Ritz E. Sympathetic innervation of the kidney in health and disease. Handbook of the Autonomic Nervous System in Health and Disease. 2003: 561-587
  • 16 Schlaich MP, Hering D, Sobotka PA et al. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep 2012; 14: 247-253
  • 17 Smith PA, Graham LN, Mackintosh AF et al. Relationship between central sympathetic activity and stage of human hypertension. Am J Hypertens 2004; 17: 217-222
  • 18 Smithwick RH, Whitelaw GP, Kinsey D. Surgical approach to the treatment of essential hypertension. Results of therapy (medical and surgical). Am J Cardiol 1962; 9: 893-899
  • 19 Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 312-319
  • 20 Strojek K, Grzeszczak W, Gorska J et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy?. J Am Soc Nephrol 2001; 12: 602-605
  • 21 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917
  • 22 Vonend O, Antoch G, Rump LC et al. Secondary rise in blood pressure after renal denervation. Lancet 2012; 380: 778
  • 23 Vonend O, Marsalek P, Russ H et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-1717
  • 24 Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565
  • 25 Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-727